tirzepatide우선순위 낮음근거 검토기타
LITERATURE DETAIL · PMID 42487666
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
Personalization of incretin therapy: can GLP-1 and GIP receptor polymorphisms influence therapy response?
- 저자
- Sandro La Vignera, Rosita A Condorelli
- 저널
- Journal of the Endocrine Society
- 공개일
- 2026 Aug
- 연구 유형
- 기타
- DOI
- 10.1210/jendso/bvag149
문헌 요약
Incretin-based therapies-glucagon-like peptide-1 receptor agonists (GLP-1RAs) such as semaglutide and the dual GLP-1/GIP receptor agonist tirzepatide-have transformed the management of type 2 diabetes (T2D) and obesity. However, substantial interindividual variability in therapeutic response remains incompletely explained by clinical factors alone. A syst…
PV 검토 포인트
누적 안전성 근거로 분류하고 기존 시그널과의 일관성을 확인합니다.